跳至主要内容
临床试验/NCT00936247
NCT00936247终止4 期

Prospective, Controlled, Single-blind, Bicentric, Randomized Study on the Safety of HES 130/0.42 Combined With a Bal. Electr. Sol. vs 5% Albumin Comb. With an Unbal. Electr. Sol. (NaCl 0.9%) in Pat. With Compensated Renal Failure

B. Braun Melsungen AG2 个研究点 分布在 1 个国家目标入组 2 人开始时间: 2009年11月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
终止
入组人数
2
试验地点
2
主要终点
Impact of two different volume replacement regimes on base excess in patients with reduced renal function

研究概览

简要总结

This investigational study will investigate two different volume replacement regimes in patients suffering from compromised renal function.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
50 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

1

Experimental

HES 130/0.42 + Sterofundin ISO

干预措施: HES 130/0.42 + electrolyte solution (Drug)

2

Active Comparator

Albumin + NaCl 0.9%

干预措施: Albumin + electrolyte solution (Drug)

结局指标

主要结局

Impact of two different volume replacement regimes on base excess in patients with reduced renal function

时间窗: from pre-operative assessment until last evaluation of data i.e. 5th (hospital) and 60th postoperative day (follow-up)

次要结局

  • Renal function, hemodynamics, blood loss, amount of given blood products, electrolytes, outcome and other data like concomitant medication(inta-/postoperative)

研究者

申办方类型
Industry

研究点 (2)

Loading locations...

相似试验

Tetraspan 6 Percent (%) Combined With Sterofundin... | 临床试验